It really depends on how you value it, mate.
The data for magrolimab in this table does not reflect excatly what was known in 2020 during it's acquisition, rather the information gained from completion of the trials that were running during the purchase. The number of patients treated were possibly a 10th of Bisantrenes. Bisantrene outperforms magrolimab in combination with an approved drug as a single agent.
Forty Seven (owner of magrolimab) were trading at AUD $4.4B prior to the takeover. AUD $2.5B is conservative for Bisantrene.
Intellectual Property (IP) Waterproofing., page-34
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.005(0.32%) |
Mkt cap ! $269.2M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.58 | $32.59K | 20.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1572 | $1.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 11.44am 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |